Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

This is a Phase IV, non-randomized, multicenter study of at least 50 evaluable subjects
diagnosed with severe hemophilia A. Enrolled subjects will be treated at home and with
in-clinic therapy exclusively with Alphanate as their sole source of Factor VIII concentrate
for prophylaxis and treatment of all bleeding episodes and surgical procedures. Subjects
will be treated for at least 2 years and a minimum of 50 exposure days, or if 50 exposure
days are not reached, for a maximum of 30 months and in accordance with the subject's usual
pre-study treatment regimen. Subjects will continue treatment as above or until they develop
inhibitors to Factor VIII at a titer greater than or equal to 5 Bethesda units (BU/ml);
Factor VIII becomes ineffective at providing hemostasis, or the subject exhibits severe or
serious adverse events that prevent completion of the study.

Inclusion Criteria:

- Male

- At least 6 years of age and not more than 65 years of age.

- Signed and dated Informed Consent Form and Patient Authorization for Release of
Information approved by the appropriate Institutional Review Board (IRB) prior to
screening and enrollment. If the subject is a minor (i.e., less than 18 years of age)
both he and his parent or legal guardian must sign and date the informed consent.

- Diagnosis of severe hemophilia A

- Levels of Factor VIII less than 0.01 IU/mL.

- Treatment with cryoprecipitate, Factor VIII concentrates, and/or whole blood, for at
least 150 cumulative exposure days (CEDs) prior to enrollment.

- No treatment with cryoprecipitate, Factor VIII concentrate, or any other blood
product, for at least 72 hours prior to screening.

- No previous diagnosis with inhibitors to Factor VIII at any detectable titer.

- Subjects must never have been diagnosed with nonspecific inhibitors of coagulation.

- Negative test for the presence of Factor VIII inhibitors at screening and enrollment.

- CD4 counts greater than or equal to 400 cells/µL.

- Vaccination against hepatitis A and hepatitis B, or evidence of antibodies against
hepatitis A and hepatitis B. (A subject who has no prior immunity against hepatitis A
will be offered a course of vaccination for hepatitis A.)

- Karnofsky Performance Score of at least 50.

Exclusion Criteria:

- Any immunosuppressive medications including intravenous immunoglobulins at the time
of enrollment.

- Clinical signs or symptoms of an infection, such as fever, chills or nausea during
screening or enrollment.

- History of frequent reactions to Factor VIII concentrates (e.g., chills or
headaches).

- Prior treatment with Alphanate® (Solvent-Detergent/ Heat-Treated).

- Immunocompromised (including HIV+ status or has an impaired immune system due to
disease or treatment).